$ALDX
Aldeyra Therapeutics Inc
PRICE
$7.06 âŒ-2.889%
Extented Hours
VOLUME
423,428
DAY RANGE
7.095 - 7.442
52 WEEK
2.36 - 9.81
Key Metrics
Market Cap
435.67 M
Beta
1.24
Avg. Volume
0.96 M
Shares Outstanding
58.32 M
Yield
0%
Public Float
0
Next Earnings Date
2022-10-27
Next Dividend Date
Company Information
Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead investigational compounds, reproxalap and ADX-629, target RASP (reactive aldehyde species), which are elevated in ocular and systemic inflammatory disease and result in cytokine release via activation of a broad array of inflammatory factors, including NF-ÎșB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in development for COVID-19 and ovarian cancer.
Website: www.aldeyra.com
HQ: ,
Related News